FDA Clears a Robot That Drives the Scope During a Colonoscopy
The US Food and Drug Administration has cleared Neptune Medical's Triton 1, a robotic system for flexible endoscopy, for diagnostic and therapeutic procedures throughout the colon. The Burlingame, Calif., company announced the clearance on Sept. 16, 2026.
Neptune says in its announcement that the system is built to keep the scope steady under robotic control along the whole length of the colon, both for routine screening and for procedures that remove precancerous growths. It argues that today's endoscopes are hard to control even for specialists with years of training, and that an unstable scope can leave part of the colon unseen.
The decision came through the FDA's 510(k) route, which settles less than the word clearance suggests. The agency does not approve a 510(k) device. It finds the device substantially equivalent to one already legally sold in the United States: the same intended use, and any differences in technology raising no new questions of safety and effectiveness. The order lets the company sell it. This is not the premarket approval pathway used for higher-risk devices, and it is not a finding that a robot-driven scope catches more cancers than one driven by hand.
The clinical evidence Neptune points to is its own first-in-human study, CARE 1, presented earlier in 2026 at Digestive Disease Week. By the company's account, the study met its primary endpoints with no adverse events, reached the far end of the colon in every case, and found at least one precancerous growth in 54.2% of patients, against an industry threshold of 35%. Endoscopists also reported a 67% lower workload than with manual colonoscopy on the NASA-TLX scale. Those are the company's own figures from a study it ran, and no independent evaluation of the system has been published.
Alex Tilson, Neptune Medical's founder and chief executive, said in the release: "Triton has the potential to fundamentally transform colonoscopy, creating a better experience for both physicians and their patients." The release gives no launch date and no price, and Tilson said the clearance "brings us one step closer to that reality."
